Almirall, S.A. LBTSF
15.35 USD +5.60 (+57.44%)
Feb 9, 2026, 9:34 AM EST
15.35 Day range 15.35
13.36 52-week range 15.47
- YTD
- -0.78%
- 1 year
- +70.37%
- Market cap
- 3.34B
- EPS (ttm)
- 0.25
- P/E ratio
- 61.40
- YTD return
- -0.78%
- 1-year return
- +70.37%
- Volume
- 100
- Open
- 15.35
- Previous close
- 9.75
- Day's range
- 15.35 – 15.35
- 52-week range
- 13.36 – 15.47
- Earnings date
- Nov 9, 2026
2Y +5.84 (+61.41%)
Next earnings
Nov 9, 2026
Expected Nov 9, 2026. Consensus EPS estimate 0.1498.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 9, 2026 | Sep 30, 2026 | 0.1498 | — | — | — |
| Jul 24, 2026 | Jun 30, 2026 | 0.1485 | 0.1484 | 0.00 | -0.07% |
| May 11, 2026 | Mar 31, 2026 | 0.104 | 0.08088 | -0.02 | -22.23% |
| Feb 23, 2026 | Dec 31, 2025 | — | 0.1057 | — | — |
| Nov 10, 2025 | Sep 30, 2025 | — | 0.06877 | — | — |
| Jul 25, 2025 | Jun 30, 2025 | — | 0.02749 | — | — |
News
Almirall Advances Skin Science and Shares New Evidence Across Its Dermatology Portfolio at EADV 2026 
Almirall, S.A. (ALMRY) Q2 2026 Earnings Call Transcript 
Almirall Announces EMA Acceptance for Filing of Paediatric Registration of Ebglyss (Lebrikizumab) in Atopic Dermatitis in Children 6 Months and Older 
Almirall, S.A. (ALMRY) Q1 2026 Earnings Call Transcript 
Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall 
AAD 2026: Almirall Presents New Clinical and Real‑world Evidence Across Atopic Dermatitis, Psoriasis, Actinic Keratosis and Acne 
Almirall, S.A. (LBTSF) Q4 2025 Earnings Call Transcript 
Almirall, S.A. (LBTSF) Presents at 44th Annual J.P. 
Almirall, S.A. (LBTSF) Q3 2025 Earnings Call Transcript 
Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target
Your note
Sign in to keep a note on LBTSF — it syncs with the Stock Master app.